TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A review in the Journal of the Endocrine Society says existing evidence suggests women with polyendocrine metabolic ovarian syndrome (PMOS), formerly called PCOS, may have a higher likelihood of Alzheimer’s disease and related dementia. The authors describe a possible association, not proof that PMOS causes dementia, and say insulin resistance and obesity may help account for the link.
A review published in the Journal of the Endocrine Society reports that women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), may be more likely to experience Alzheimer’s disease and related dementias. The authors say current evidence points to a possible association, potentially linked to conditions such as insulin resistance and obesity, rather than establishing that PMOS itself causes dementia.
The researchers conducted a PubMed search of studies available through October 2025 and reviewed evidence about PMOS, brain health and dementia-related pathways. They concluded that people with PMOS may face greater risk of changes in memory, thinking and brain health, but the review does not establish a direct cause-and-effect relationship or quantify an individual woman’s likelihood of developing dementia.
The review describes mild but reproducible impairments in executive function and memory among patients with PMOS, along with reported structural and functional brain alterations. These findings could be relevant to Alzheimer’s disease and related dementias, but they do not mean that those cognitive differences are themselves a diagnosis of dementia or proof that the condition will progress to it.
Co-author Ricardo Azziz, of the University of Alabama at Birmingham, said the available evidence suggests that any relationship may be mediated by common metabolic conditions, particularly insulin resistance and obesity. The review was funded by the Foundation for Research and Education Excellence. Its other authors are affiliated with Tehran University of Medical Sciences, the foundation, the University of Southern California and the University of Alabama at Birmingham.
Metabolic Health May Shape the Link
The review draws attention to a potential connection between reproductive and metabolic health and later-life brain health. PMOS is reported to affect 10% to 15% of women worldwide and is associated with a range of health issues, including diabetes and heart disease. If future research confirms that metabolic complications help explain dementia-related risk, it could clarify which parts of the association deserve closer study.
For readers, the report is a signal of a research question, not a basis for predicting an individual outcome. It does not show that PMOS inevitably leads to Alzheimer’s disease, nor does it demonstrate that treating PMOS prevents dementia. The authors’ emphasis on metabolic comorbidities makes it especially important to distinguish the syndrome itself from health conditions that may occur alongside it.
The findings could help researchers identify shared biological pathways and guide future studies of prevention or treatment. Azziz said understanding how the two conditions may be related could reveal common causes and pathways that might inform future treatment development. That possibility remains a research aim, not a result demonstrated by this review.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
As an affiliate, we earn on qualifying purchases.
What the Review Examined
PMOS is the name used in the source report for a condition formerly known as polycystic ovary syndrome (PCOS). The report says the condition can have lifelong effects and is associated with concerns including diabetes, cardiovascular disease, stroke, depression, anxiety, infertility and endometrial cancer. It may also affect males, though in different ways; the review’s reported concern here is the possible association with dementia in women.
The article, titled “Potential links between PCOS/PMOS and Alzheimer disease and related dementias,” was published in 2026 in the Journal of the Endocrine Society (DOI: 10.1210/jendso/bvag206). It is a review of existing evidence, rather than a report of a new clinical trial or a study that followed a defined group of women over time. The authors searched PubMed from its inception through October 2025.
That design means the paper brings together earlier findings and identifies possible patterns and research gaps. It does not, by itself, establish how frequently dementia occurs in people with PMOS compared with those without the syndrome. The source report describes an inferred risk and proposed pathways, rather than a confirmed causal mechanism.
“Current evidence suggests that any association between PMOS and Alzheimer’s disease and dementia is likely mediated by metabolic comorbidities, particularly insulin resistance and obesity, rather than an independent effect of PMOS itself.”
— Ricardo Azziz, study co-author at the University of Alabama at Birmingham
Cause and Risk Still Unsettled
The review does not establish whether PMOS independently increases the risk of Alzheimer’s disease or related dementia, or whether the observed relationship is mainly associated with insulin resistance, obesity or other metabolic conditions. The source report does not provide a numerical estimate of increased risk, a comparison rate, or a timeframe for any possible change in risk.
It is also unclear which findings come from evidence strong enough to show that cognitive or brain changes precede dementia, and whether those findings apply across different groups of people with PMOS. The review identifies gaps in knowledge; further research would be needed to test the proposed pathways and separate the effects of the syndrome from those of accompanying conditions.
As a review of existing research, the paper’s conclusions depend on the scope and quality of studies available through its search cutoff in October 2025. The report does not describe a clinical recommendation or a proven way to prevent dementia for people with PMOS. Individual medical decisions should be discussed with a qualified health professional.
Research Needed to Test the Link
The authors identify gaps in the evidence and areas for future research, but the source report does not name a specific upcoming trial, follow-up study or publication date. Further studies would need to establish whether the observed cognitive and brain findings predict later dementia, and to assess how much any association is explained by metabolic conditions that occur alongside PMOS.
Researchers will also need to clarify the pathways potentially shared by PMOS and Alzheimer’s disease and related dementias before the findings can support prevention strategies or treatment development. Until those questions are tested, the review should be read as a report of a possible association and a case for further investigation—not proof of causation or a prediction for any individual.
Key Questions
Does PMOS cause Alzheimer’s disease?
The review does not establish that PMOS causes Alzheimer’s disease. It reports a possible association and says metabolic conditions, including insulin resistance and obesity, may help explain it.
What does the review say about dementia risk?
The authors say existing evidence suggests women with PMOS may be more likely to experience Alzheimer’s disease and related dementias. The source report gives no numerical risk estimate or comparison rate, so it cannot quantify an individual’s risk.
What is PMOS?
PMOS is the term used in the source report for a condition formerly known as polycystic ovary syndrome (PCOS). The report says it is associated with a range of reproductive, metabolic and other health concerns.
What research did the authors review?
The authors searched PubMed for existing research from the database’s inception through October 2025. Their 2026 paper is a review, not a new clinical trial following participants over time.
Does the review recommend a dementia-prevention treatment?
No. The report identifies a possible relationship and areas for future research, but does not establish a proven prevention or treatment for dementia in people with PMOS. For personal health decisions, consult a qualified professional.
Source: rss
